Home infusion clinical services will be reimbursed in the Medicare Part B program starting on January 1, 2019. This new law, established by Congress as part of the Bipartisan Budget Act of 2018, provides for clinical services reimbursement for a limited set of home infusion drugs in the Medicare Part B Durable Medical Equipment benefit. Provisions of the law will affect home infusion providers and suppliers, home health agencies, and other companies in the industry.
On October 31, CMS issued a final rule that could inhibit beneficiary access to home infusion services. Take action to ensure this rule does not render home infusion reimbursement unsustainable.
Other materials are included on the member-only resources page. NHIA member companies can use these resources to garner a full understanding of the regulation, including detailed analysis of the new law, answers to frequently asked questions, and insight into the Centers for Medicare and Medicaid Services’ implementation of the law. The site also provides information on efforts underway related to the Medicare Home Infusion Site of Care Act. This new transitional reimbursement law is the springboard to developing policy that may, in the future, include clinical service reimbursement for Medicare Part D infusion drugs.